Added to YB: 2026-06-10
Pitch date: 2026-04-14
RDY [bearish]
Dr. Reddy's Laboratories Limited
Author Info
No bio for this author
Company Info
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Market Cap
INR 1.1T
Pitch Price
N/A
Price Target
7.00
Dividend
0.63%
EV/EBITDA
15.08
P/E
24.81
EV/Sales
3.14
Sector
Pharmaceuticals
Category
value
Dr. Reddy's Laboratories Limited - $RDY (short)
RDY (short): Revlimid cliff thesis. Generic Revlimid exclusivity expired Jan'26; 90%+ pricing erosion underway, a ~$400mn EBITDA headwind (65% of peak EBITDA). No offset—generic Ozempic rejected by Health Canada Oct'25. FY27e EPS $0.37 vs $0.60 consensus (40% below). PT $7, ~50% downside. Catalyst: 4Q26 earnings May'26 + sell-side revisions. Risks: faster Ozempic approval, M&A, INR depreciation.
Read full article (6 min)